Healthcare Industry News: kidney disease
News Release - December 6, 2007
Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study DataNo Safety Concerns Raised Sulodexide Phase 3 study to continue without modification
NEW YORK, Dec. 5 (HSMN NewsFeed) -- Keryx Biopharmaceuticals (Nasdaq: KERX ) today announced that the Independent Data Safety Monitoring Committee (DSMC) responsible for monitoring Sulonex(TM) (sulodexide oral gelcaps), the Company's lead drug candidate under development as a treatment for diabetic nephropathy, recently met to evaluate the data from the ongoing Phase 3 trial. Following a complete review of all available safety and efficacy data, the DSMC found no cogent reason to recommend alteration or termination of the Phase 3 trial. The DSMC raised no safety concerns regarding Sulonex or the trial. As planned, no review was conducted of the safety and efficacy data from the Phase 4 trial during this meeting.
Prior to this most recent meeting, the DSMC had previously convened in November 2006, in March 2007 and in August 2007 to review data from the Phase 3 and Phase 4 studies. At each of these meetings the DSMC raised no safety concerns.
On June 18, 2007, the Company announced the completion of patient randomizations into the Phase 3 portion of the clinical registration program. The Company anticipates that the last patient will complete the active treatment period in mid-December 2007 and the two month off-treatment period in mid-February 2008.
ABOUT THE SULONEX(TM) PHASE 3 and PHASE 4 CLINICAL PROGRAM
Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. These trials are being conducted by the Collaborative Study Group, the world's largest standing renal clinical trials group.
The clinical plan to support an NDA approval for Sulonex(TM) under Subpart H (accelerated approval), as agreed upon with the FDA under an SPA, consists of: (i) a single Phase 3 trial in patients with microalbuminuria based on the surrogate marker of regression of microalbuminuria as the primary endpoint; (ii) supportive data from previously conducted clinical studies; and (iii) substantial recruitment into our Phase 4 confirmatory study that will measure clinical outcomes in patients with overt nephropathy, or macroalbuminuria.
The Phase 3 clinical program is a multi-center, randomized, double-blind, placebo-controlled study, comparing 200 mg daily of Sulonex(TM) versus placebo, with a 1:1 randomization between the two arms. The objective of this study is to determine the safety and efficacy of sulodexide in the treatment of patients with type 2 diabetes and persistent microalbuminuria, or diabetic nephropathy, despite being treated with a maximum approved or tolerated dose of an angiotensin II receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEi). The study is designed for patients to be on treatment for six months, followed by two months of evaluation off-treatment.
During the treatment and off-treatment evaluation period, all patients in the study population are expected to continue to receive maximum approved or tolerated doses of ACEis or ARBs. Patients who were not already on maximum approved or tolerated doses of ACEis or ARBs for 120 days were required to go into a run-in period prior to randomization of up to 120 days. This run-in period was designed to stabilize blood pressure and to confirm persistent microalbuminuria while the patients are treated with maximum approved or tolerated doses of ACEis or ARBs.
The primary endpoint for the Phase 3 clinical trial is "therapeutic success" at 6 months, where therapeutic success is defined as (i) conversion from microalbuminuria to normoalbuminuria, as measured by albumin/creatinine ratio (ACR), with at least a 25% reduction in ACR relative to baseline ACR, or (ii) a 50% reduction in ACR relative to baseline ACR.
Concurrently with the Phase 3 clinical trial, the Company is continuing enrollment into its Phase 4 clinical trial, which is a randomized, double- blind, placebo-controlled study, also comparing 200 mg daily of Sulonex(TM) versus placebo, with a 1:1 randomization between the two arms. The objective of this Phase 4 study is to determine the efficacy of Sulonex(TM) in reducing the rate of progression to End-stage renal disease and adverse clinical sequelae in patients with type 2 diabetes and macroalbuminuria or overt diabetic nephropathy, despite being treated with a maximum approved or tolerated dose of an ARB. All patients in the Phase 4 study population are expected to continue to receive maximum approved or tolerated doses of ARBs during the course of the study. The Phase 4 study is designed to enroll approximately 2,200 patients.
The Company has committed to the FDA, as a condition to the approval of Sulonex(TM) based on the Phase 3 clinical trial under the guidelines of accelerated approval, that the Phase 4 study would be substantially enrolled at the time of the filing of the NDA for Sulonex.
Sulonex (sulodexide oral gelcap) belongs to a proposed new class of nephroprotective, or kidney protecting, drugs, known as the glycosaminoglycans. A variety of members of this chemical family have been shown to decrease pathological albumin excretion in diabetic nephropathy in humans. Some of the members of this chemical family include the following approved drugs: standard heparin, low molecular weight heparin and danaparoid. These agents all require therapy by injection and are all potent anticoagulants, which are blood thinners capable of inducing bleeding. Sulonex, on the other hand, is given orally and, in this form, has demonstrated little, if any, anticoagulant effects to date.
Keryx owns the exclusive rights to use Sulonex(TM) for the treatment of diabetic nephropathy in North America, Japan and certain other markets outside of Europe. Diabetic nephropathy is a long-term complication of diabetes in which the kidneys are progressively damaged. Sulonex is a glycosaminoglycan compound with structural similarities to the broad family of marketed heparins and low molecular weight heparins. This drug has been marketed in a number of European, Asian and South American countries for many years by our licensor for certain cardiovascular conditions and has an established safety profile at the doses used for such indications. Additionally, it has been demonstrated in multiple clinical trials conducted in Europe and the U.S., including two randomized, double-blind, placebo-controlled Phase II studies, that Sulonex can reduce urinary protein excretion in patients with diabetic nephropathy.
Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment, or SPA, with the Food & Drug Administration, or FDA. These trials are being conducted by the Collaborative Study Group, or the CSG, the world's largest standing renal clinical trials group.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphorous and form non- absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical- stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in- class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
Some of the statements included in this press release, particularly those anticipating future performance, future results from the Phase 3 and Phase 4 clinical trials, timelines for the completion of the Sulonex(TM) pivotal clinical trial program, including the Phase 3 and the Phase 4 clinical trials, the number of patients and clinical sites included in the Phase 3 and Phase 4 clinical trials, expectations regarding FDA approval and commercial launch of Sulonex(TM), market size estimates for Sulonex(TM), growth and operating strategies, safety and/or efficacy of Sulonex(TM), and similar matters, are forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward- looking statements contained in the Private Securities Litigation Reform Act of 1995. Important factors may cause our actual results to differ materially, including: our ability to successfully complete the Sulonex(TM) pivotal clinical program on a cost- effective basis; failure to meet the endpoints of the Phase 3 or Phase 4 studies; and other risk factors identified from time to time in our SEC reports, including, but not limited to, the report on Form 10- K for the year ended December 31, 2006, and our quarterly report on Form 10-Q for the quarter ended September 30, 2007. Any forward-looking statements set forth in this news release speak only as of the date of this news release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com/. The information in Keryx's website is not incorporated by reference into this press release and is included as an inactive textual reference only.
Source: Keryx Biopharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.